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The initiation of HIV-1 reverse transcription occurs at an 18-nucleotide sequence in the viral genome designated as the primer binding site
(PBS), which is complementary to the 3Vterminal nucleotides of tRNALys,3. Since the PBS is highly conserved among all infectious HIV-1, it
represents an attractive target for the development of new therapeutics to inhibit viral replication. In this study, we have evaluated three
approaches using small interfering RNA (siRNAs) targeted to the PBS for the capacity to inhibit HIV-1 replication. In the first, transfection of
a 21-nucleotide siRNA complementary to the PBS into cells inhibited production of HIV-1 following infection. Control siRNAs of the same
length complementary to HIV-1 gag mRNA or to gfp mRNA decreased the production of virus or had no effect on virus replication,
respectively. Analysis of the PBS of integrated proviruses derived from viruses that ultimately grew in cultures transfected with siRNA all
contained wild-type PBS sequence, demonstrating that HIV-1 did not mutate to escape inhibition by siRNA. In the second approach, hairpin
siRNA targeted to the wild-type PBS were expressed using an adeno-associated virus (AAV) vector. HIV-1 replication was inhibited in cells
infected with AAV encoding the siRNA to the wild-type PBS, but not in cells infected with AAV encoding an siRNA of the same length
targeted to an irrelevant PBS. Finally, studies from this laboratory have shown that alteration of the PBS to be complementary to tRNAHis
results in the production of infectious virus that rapidly reverts to utilize tRNALys,3 following in vitro culture. A proviral genome containing a
PBS complementary to tRNAHis that encodes an siRNA molecule complementary to the wild-type PBS under control of a U6 promoter
within the nef gene was as infectious as the parent HIV-1 genome containing no insert in nef. The virus with the PBS only complementary to
tRNAHis reverted to use tRNALys,3, coincident with rapid virus growth, while the virus encoding siRNA grew slower than the virus without
siRNA and maintained the PBS complementary to tRNAHis longer in culture. At later times of infection, viruses with the PBS
complementary to tRNAHis and the siRNA exhibited a rapid increase in p24 antigen in the culture. Analysis of the PBS revealed that it was
now complementary to tRNALys,3. Analysis of the gene encoding the siRNA revealed that the reversion of the PBS coincided with the
deletion of the gene encoding siRNA. The results of these studies show that siRNA targeted to the PBS of HIV-1 can inhibit virus replication,
supporting the concept that HIV-1 has evolved a strong preference to select tRNALys,3 for high-level replication and establishing the PBS and
primer selection as a potential target for new therapeutics.
D 2004 Elsevier Inc. All rights reserved.
Keywords: HIV; siRNA; Primer binding siteIntroduction
An essential step in the replication of human immuno-
deficiency virus (HIV-1) is the process in which the viral0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.09.027
* Corresponding author. Department of Cell Biology, University of
Alabama at Birmingham, 802 Kaul Building, 720 20th Street South,
Birmingham, AL 35294. Fax: +1 205 934 1580.
E-mail address: caseym@uab.edu (C.D. Morrow).RNA genome is converted into a DNA intermediate prior to
integration into the host cell genome. This process, termed
reverse transcription, is carried out by a virally encoded
enzyme, reverse transcriptase (RT) (Baltimore, 1970; Temin
and Mizutani, 1970). In order to initiate reverse tran-
scription, RT requires a primer; retroviruses utilize a tRNA
primer for initiation of reverse transcription. The tRNA
primer is complementary to a region in the viral RNA
genome, designated as the primer-binding site (PBS) (Panet04) 221–232
W. Han et al. / Virology 330 (2004) 221–232222and Berliner, 1978; Peters and Dahlberg, 1979; Temin,
1981). The PBS is an 18-nucleotide region that is
complementary to the 3V terminal 18 nucleotides of the
primer used for initiation of reverse transcription (Gilboa et
al., 1979; Taylor and Hsu, 1980; Varmus, 1982). During the
process of reverse transcription, the RT copies the attached
tRNA primer to regenerate the PBS and the proviral genome
(Gilboa et al., 1979; Taylor, 1977; Varmus, 1982). Thus, the
PBS found in proviral genomes is indicative of the tRNA
primer used for initiation of reverse transcription.Several
inherent features of the PBS make it an attractive target for
development new therapeutics to inhibit replication. All
known strains of HIV-1 use a specific tRNA, tRNALys,3, as
the primer for initiation of reverse transcription (Mak and
Kleiman, 1997; Marquet et al., 1995; Muesing et al., 1985;
Ratner et al., 1985). Previous studies from this laboratory
and others have shown that changing the PBS of HIV-1 to
be complementary to alternate tRNAs allows HIV-1 to
utilize these tRNAs for reverse transcription (Das et al.,
1995; Li et al., 1994; Wakefield et al., 1995). However, all
of these viruses eventually reverted to utilize tRNALys,3 for
replication, highlighting the strong preference for HIV-1 to
select tRNALys,3. One of the more thoroughly characterized
HIV-1 that utilizes an alternate tRNA primer is a virus that
utilizes tRNAHis for initiation of reverse transcription
(Wakefield et al., 1996; Zhang et al., 1998). In this virus,
HIV-1 with a PBS complementary to tRNAHis reverts back
to utilize tRNALys,3 following a short-term in vitro culture.
However, substitutions of nucleotides within the A loop that
are complementary to the anticodon of tRNAHis along with
a PBS complementary to the 3V terminal nucleotides of
tRNAHis results in a virus that can stably utilize tRNAHis for
replication (Wakefield et al., 1996; Zhang et al., 1996,
1998). Analysis of this virus has revealed that although it
stably maintains a PBS complementary to tRNAHis, the
infectivity of this virus is less than that of the wild-type
virus (Moore et al., 2004).
RNAi interference (RNAi) is an evolutionarily conserved
mechanism of sequence-specific gene silencing. It was first
described in Caenorhabditis elegans, where long double-
stranded RNA (dsRNA) was shown to produce sequence-
specific gene silencing (Fire et al., 1998). These long
double-stranded RNAs are processed into 21- to 23-base-
pair small interfering RNAs (siRNAs) by an enzyme called
Dicer, which are then incorporated into a ribonucleoprotein
complex called RISC (RNA induced silencing complex). In
the RISC, the antisense strand of the siRNA serves as a
guide for the degradation of the homologous RNA target. In
mammalian cells, the innate interferon immune response,
including activation of the dsRNA-dependent protein kinase
PKR, is triggered by long dsRNAs (Kumar and Carmichael,
1998). Shorter 21- to 23-base-pair siRNAs do not appear to
activate PKR and the cellular interferon response (Caplen et
al., 2001; Elbashir et al., 2001). siRNAs have been shown to
inhibit viral replication or block gene expression in cell
culture systems for several viruses including poliovirus,hepatitis C virus, hepatitis B virus, HPV, and HIV-1 (Boden
et al., 2003a; Capodici et al., 2002; Coburn and Cullen,
2002; Gitlin et al., 2002; Jacque et al., 2002; Jiang and
Milner, 2002; Lee et al., 2002; Novina et al., 2002; Park et
al., 2003; Shlomai and Shaul, 2003; Surabhi and Gaynor,
2002; Wilson et al., 2003). The expression of HIV-1 viral
proteins as well as cellular receptors for HIV-1 have been
targeted by siRNAs and cause decreased levels of virus
production (Anderson et al., 2003; Boden et al., 2003a;
Capodici et al., 2002; Chiu et al., 2004; Coburn and Cullen,
2002; Jacque et al., 2002; Kameoka et al., 2004; Lee et al.,
2002; Martinez et al., 2002; Novina et al., 2002; Park et al.,
2003; Song et al., 2003; Surabhi and Gaynor, 2002).
siRNAs targeted to the TAR regulatory region and nef of
the HIV-1 genome have also been shown to be effective at
reducing the level of virus production and the presence of
reverse transcription intermediates, indicating that genomic
HIV-1 RNA can be used as a target for siRNAs (Das et al.,
2004; Jacque et al., 2002).
In the current study, we have analyzed the effect of
siRNA targeted to the PBS on HIV replication. Transfection
of siRNA resulted in a transient inhibition of virus
replication in SupT1 cells. Expression of a short hairpin
siRNA from an adeno-associated virus (AAV) vector in cells
also resulted in inhibition of HIV-1 replication. Finally, we
used a HIV-1 provirus with a PBS complementary to
tRNAHis for expression of siRNA targeted against the wild-
type PBS and analyzed the replication and stability of the
PBS and siRNA following sequential replication of this
virus in SupT1 cells. Viruses with the siRNA targeted to the
wild-type PBS had an increased stability of the PBS
complementary to tRNAHis. The results of these studies
are discussed with respect to the insights into the mecha-
nism of primer selection and the impact of inhibiting this
process on viral replication.Results
siRNA targeted to the PBS inhibits production of infectious
virus
Although previous studies have shown that siRNA
targeted to different regions of the HIV-1 genome can
inhibit virus replication (Boden et al., 2003a; Capodici et al.,
2002; Coburn and Cullen, 2002; Jacque et al., 2002; Lee et
al., 2002; Novina et al., 2002; Park et al., 2003; Surabhi and
Gaynor, 2002), the necessity for sequence complementarity
and capacity of HIV-1 to induce mutations limits the
potential to inhibit replication. Because of the conservation
of the PBS sequence, we chose to produce a siRNA
complementary to this 18-nucleotide sequence (Fig. 1A).
The double-stranded siRNA contained 3Voverhangs with 21
base pair complementary regions; note that of the 21
nucleotides, 18 comprise the PBS with the additional 3
nucleotides found in U5 region flanking the PBS. In
Fig. 2. Inhibition of HIV-1 by siRNA. (A) The amounts of p24 on indicated
days after transfection of SupT1 cells with siRNA targeted to viral gag
mRNA or gfp mRNA followed by infection with HIV-1 (derived from
transfection of the proviral plasmid pNL4-3). These siRNAs served as
positive (gag) and negative (gfp) controls for the effects of siRNAs on the
production of virus. A representative experiment is shown in which the
siRNAs were transformed effectively to produce positive and negative
control results. (B) The amounts of p24 on indicated days after transfection
and infection of SupT1 cells with siRNA targeted to the PBS or with no
siRNA transfected followed by infection with HIV-1 derived from pNL4-3.
This representative experiment is shown where both the positive (gag) and
negative (gfp) siRNAs gave predicted results.
Fig. 1. U5-PBS of HIV-1 and siRNAs. (A) m-fold structure of wild-type
U5-PBS region of HIV-1 complementary to tRNALys,3 primer for reverse
transcription. The 18 nucleotides of PBS are shaded and in bold. (B)
Sequences of siRNAs. The gag sequence from Capodici et al. (2002) and
gfp sequence from Novina et al. (2002). The 18 nucleotides of the PBS are
in boldface for PBS siRNA.
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control for inhibition, we used an siRNA targeted to gfp as a
negative control (Fig. 1B).
The siRNAs were transfected into SupT1 cells and
subsequently infected with 50 pg HIV-1 NL4-3 (a MOI of
approximately 0.01). In preliminary studies using fluores-
cent RNA oligomers, we determined that the majority of
the cells were transfected using the lipofectin procedure
(data not shown). However, the transfection efficiency and
thus the magnitude of the inhibition by siRNA varied
between individual experiments. The positive control
siRNA targeted to the HIV-1 gag mRNA, previously
shown to inhibit viral replication (Capodici et al., 2002),
decreased the levels of p24, while the negative control
siRNA molecule targeted to gfp mRNA showed no effect
on the levels of p24; that is, at day 10, the siRNA targeted
to gag resulted in approximately a 100-fold inhibition of
virus production (Fig. 2A). In all experiments where the
siRNA targeted to gag inhibited virus replication, we found
a corresponding inhibition of virus production by siRNA
targeted to the PBS (Fig. 2B). Note that the effects of the
siRNA to gag and the PBS, most evident at day 10, are due
to a lag in virus production caused by RNA interference
earlier in the culture. At later times, the virus production of
these cultures (past day 15) was similar to the no siRNA
and gfp cultures (data not shown). Experiments using
siRNAs targeted to other areas of the U5 region though,
including the A stem and loop, did not show consistentdecreases in the production of virus as was shown for
siRNA targeted to the PBS (data not shown).
The siRNA targeted to PBS region contains sequence
that is complimentary to not only the PBS, but also the 3V18
nucleotides of the tRNA primer that binds the PBS. To
determine if the effects on virus growth when cells were
transfected with the PBS siRNA were due to degradation of
tRNALys,3 in the cells, the levels of tRNALys,3 were
compared when cells were transfected with different
siRNAs. SupT1 cells were transfected with siRNAs and
collected 2 days after transfection. Total RNA was prepared
from the cells and relative levels of tRNALys,3 and tRNAMet
Fig. 3. Inhibition of HIV infection by AAV expression siRNA. (A, B)
cDNAs encoding hairpin siRNAs targeted to PBS complementary to
tRNALys,3 (Panel A—AAV-Lys) or tRNAGlu (Panel B—AAV-Glu) were
constructed and positioned downstream of a U6 promoter. The predicted
siRNA hairpins are depicted. (C) Inhibition of HIV-1 replication by AAV
encoding siRNA targeted to the wild-type PBS. SupT1 cells were first
infected with AAV using siRNAs targeted to the wild-type PBS (AAV-Lys)
or a PBS complementary to tRNAGlu (AAV-Glu). After 24 h, the cells were
counted and the same number of pelleted cells were then infected with NL4-
3 HIV-1 and the infection was monitored by p24 ELISA antigen capture.
Data presented are representative of three independent experiments.
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PBS siRNAs did not decrease the levels of either tRNALys,3
or the control tRNAMet as compared to no siRNA trans-
fection control (data not shown). These results indicate that
the PBS and gag siRNAs do not affect the production of
HIV-1 by decreasing the levels of tRNALys,3. One possible
explanation for the inhibition of HIV-1 replication by
siRNAs would be the global inhibition of cellular and viral
protein synthesis due to activation of PKR (Caplen et al.,
2001; Elbashir et al., 2001; Kumar and Carmichael, 1998).
Although this seems unlikely since the siRNA targeted to
gfp did not inhibit virus production, we examined the level
of protein synthesis by metabolic labeling of proteins in
SupT1 cells after transfection with different siRNAs. Cells
were transfected and translabeled with 35S-translabel 48 h
later; 35S levels were determined for cells transfected with
the different siRNAs. No significant difference was seen in
the levels of protein synthesis in cells transfected with any
of the siRNAs, indicating the inhibition by the gag and PBS
siRNAs were not due to overall inhibition of protein
synthesis (data not shown).
The invariance of the PBS sequence makes it an
attractive target for siRNA because the sequence is not
likely to change to escape the effects of this siRNA. RNAi is
highly sensitive to changes in its target sequence. A single
point mutation in the tat gene was shown to render HIV-1
that was initially sensitive to a short hairpin siRNA targeted
to that region resistant to the siRNA (Boden et al., 2003a).
Any change in the sequence of the PBS after exposure to the
PBS siRNA would be due to mutation to escape the effects
of the siRNA. To address this issue, the sequences of the
HIV-1 PBS 14 days after transfection with PBS siRNA and
infection with HIV-1 were examined to determine if escape
mutants were present in the viral population that could be
resistant to the PBS siRNA. The PBS sequences of
integrated proviruses isolated from high molecular weight
DNA 14 days after transfection with siRNA and infection
with HIV-1 were determined. All proviral clones isolated
from cells transfected with the PBS siRNA contained wild-
type PBS sequences, as did proviral clones isolated from
cells transfected with another siRNA (gag). These results
indicate that during the short time the PBS siRNA is present
in the cells, it does not select virus that has mutated the
sequence of the PBS to escape the effects of the siRNA
(data not shown).
Inhibition of HIV-1 replication using siRNA targeted to the
PBS expressed from an adeno-associated virus (AAV)
Although it was clear that siRNA targeted to the PBS
could inhibit HIV-1 replication, the effect was transient,
most probably due to the dilution of the siRNAs with cell
division. To further demonstrate the capacity of siRNA
targeted to the PBS to inhibit HIV replication, we wanted
to express the siRNA from a cDNA to determine if we
could obtain a more robust and sustained inhibition. Arecent study found that siRNAs expressed from lentivirus
vectors targeted to the PBS did not inhibit HIV replication
(Das et al., 2004). In a previous study, we had also noted a
reduction in the expression of a small RNA (tRNA) using
the U6 RNA pol III promoter following integration of a
MuLV vector into the host cell chromosome (Palmer and
Morrow, 2004). To circumvent this issue, we utilized an
adeno-associated virus (AAV) vector. The siRNA gene was
expressed from a U6-RNA polymerase III promoter with
termination occurring at a run of T’s following the siRNA.
The predicted structure for this siRNA would be in the
form of a hairpin that is complementary to the 18
nucleotides of the wild-type HIV-1 PBS (Fig. 3A). As a
control, we designed a second siRNA targeted to a PBS
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this laboratory has found that HIV-1 with a PBS
complementary to tRNAGlu stably maintains this PBS over
extended culture (Dupuy et al., 2003). To avoid any
complications from added helper virus, we utilized an
AAV three plasmid complementation system; plasmids
encoding the genes for siRNA to PBS complementary to
tRNALys,3 or tRNAGlu positioned downstream of the U6
RNA pol III promoter were co-transfected with plasmids
encoding the AAV associated genes (rep and cap) and the
requisite adenovirus genes needed for AAV replication.
Following transfection into HEK293 cells, the AAV was
concentrated by ultracentrifugation; the titer of the
recombinant AAVs were estimated by comparison with a
control vector that encoded betagalactosidase (h-gal).
SupT1 cells were infected with an approximate MOI of
5 with the recombinant AAV expressing siRNA targeted to
the wild-type PBS (AAV-Lys) or a PBS complementary to
tRNAGlu (AAV-Glu). Based on parallel infections using the
AAV that express h-gal, we estimate that 70–80% of the
cells are infected under these conditions (data not shown).
After 24 h, we determined the ability of wild-type HIV-1
to infect and grow in the AAV infected SupT1 cells (Fig.
3C). Analysis of p24 levels revealed a clear difference
from cells with AAV-Glu compared to AAV-Lys. In this
experiment, a 2-week delay in the production of HIV-1
was found in cells infected with AAV with siRNA targeted
to the wild-type PBS (AAV-Lys). In a related experiment,
we found no substantial inhibition of HIV replication in
cells infected with AAV that did not encode a RNAi (data
not shown). Finally, cells infected with AAV-Lys or AAV-
Glu showed similar growth, indicating that the inhibition
seen was not due to the toxicity of the AAV-vector (data
not shown). Eventually, a virus was detected in cultures
infected with AAV-Lys and reached amounts comparable
to that seen in cells infected with AAV-Glu. Sequence
analysis of the PBS of the viruses that grew in these
cultures revealed they were all wild-type, complementary
to tRNALys,3, indicating that HIV-1 did not alter the
sequence of the PBS to escape the effects of the siRNA.
Thus, the delivery of siRNA by AAV also resulted in an
inhibition of HIV-1 replication.
Replication of HIV-1 encoding siRNA targeted to PBS
The capacity of siRNA targeted to the PBS to inhibit or
retard wild-type virus replication provided us with a tool to
further investigate the preference of HIV-1 to select
tRNALys,3 for replication. Previous studies have described
the construction of HIV-1 proviral genomes in which the
PBS has been altered to be complementary to the 3V
terminal nucleotides of tRNAHis (Wakefield et al., 1996).
However, these viruses rapidly revert back to use tRNALys,3
unless compensating mutations are made 5V to the PBS in
the A-loop region, which is complementary to the
anticodon loop of the tRNA primer. Although certainmutations were favored, we have observed a variety of
single nucleotide changes within this region upon analysis
of integrated proviruses; some of these mutations can have
drastic effects on the stability of the PBS causing rapid
reversion to the wild-type PBS complementary to
tRNALys,3 (Zhang et al., 1998). The presence of an siRNA
to the wild-type PBS encoded within a virus with a PBS
complementary to tRNAHis might allow for the selection of
HIV-1 that effectively uses tRNAHis for replication by
suppression of reversion of the PBS. We chose to clone the
siRNA targeted to the wild-type PBS into the nef gene. The
siRNA is expressed from a U6 RNA polymerase III
promoter with termination occurring at a run of T’s
following the siRNA (Fig. 4A). A second virus was
constructed to serve as a negative control in which the
siRNA was designed to be complementary to a PBS
complementary to tRNAGlu.
We first examined the production of infectious virus
following transfection of proviral genomes into COS-1
cells. Supernatants from COS-1 cells transfected with NL4-
His and NL4-His encoding the siRNA [NL4-His-
RNAi(Lys,3)] were analyzed for p24 antigen using an
ELISA (Fig. 4B). Thus, the inclusion of the genes encoding
siRNA did not affect the production of virus. We also tested
the infectivity of viruses released from the transfected cells
using a JC53-BL indicator cell line (Derdeyn et al., 2000).
The infectivity of the virus that uses tRNAHis as the primer
for reverse transcription was considerably less than that of
the wild-type virus (data not shown). However, the
infectivity of the NL4-His-RNAi(Lys,3) virus was similar
to that for NL4-His virus (Fig. 4C). Thus, the inclusion of
the siRNA molecule did not result in a deleterious effect on
viral gene expression or production of infectious virus.
Finally, the NL4-His virus encoding siRNA to a PBS
complementary to tRNAGlu [NL4-His-RNAi(Glu)] had
similar infectivity to NL4-His-RNAi(Lys,3) (data not
shown).
We next analyzed the expression of the siRNA follow-
ing transfection into COS-1 cells. For these studies, total
RNA was isolated from cells transfected with NL4-His,
NL4-His-RNAi(Lys,3) NL4-His-RNAi(Glu) followed by
Northern blot analysis. As shown in Fig. 4D, the
production of the Lys,3 siRNA molecule was detected in
cells transfected with NL4-His-RNAi(Lys,3) but as
expected, not in cells transfected with NL4-His or NL4-
His-RNAi(Glu). The size of the RNA correlates with the
predicted size of the siRNA.
Infection of SupT1 cells by NL4-His and NL4-His-
RNAi(Lys,3) was initiated with cell-free supernatant
obtained from transfection of COS-1 cells with approx-
imately equal amounts of infectious virus. The infection
was monitored by the presence of p24 antigen in the
culture supernatant. The replication of NL4-His was
consistent with that found in our previous studies. Low-
level replication occurred for a period of time in SupT1
cells followed by a rapid increase in p24 in the culture
Fig. 4. HIV-1 proviral genome with a PBS complementary to tRNAHis that encode RNAi. (A) Schematic of HIV-1 genome. Depicted are the 5Vand 3VLTR and
coding regions of the HIV-1 genome. The genes encoding siRNAs as well as a U6 promoter and stretch of thymidines that serve as a terminator for pol III were
cloned into the nef gene as depicted. (B) Production of virus following transfection. The plasmids NL4-His and NL4-His-RNAi(Lys,3) were transfected into
COS-1 cells and the amounts of p24 antigen released into the supernatants were determined at 48 h post-transfection using an ELISA. The data presented is
representative from three individual transfections. In each experiment, there was no significant difference between the amounts of p24 produced by the virus
derived from NL4-His compared to NL4-His-RNAi (Lys,3). (C) Infectivity of viruses. The amounts of infectious virus produced from transfection of pNL4-His
or pNL4-His-RNAi(Lys,3) was determined using the JC53-BL bioassay. The numbers of infectious units was then divided by the amounts of p24 antigen
produced to provide the relative infectivity of each of the two samples. Results shown are representative from three independent experiments; in all
experiments, NL4-His and NL4-His-RNAi(Lys,3) gave similar infectivities following transfection. (D) Expression of RNAi. COS-1 cells were transfected with
NL4-His, NL4-His-RNAi(Lys,3), or NL4-His-RNAi(Glu). After 48 h, total RNAwas isolated and 10 Ag of each sample separated on an agarose gel. Following
transfer to nitrocellulose, the blot was probed with a labeled oligonucleotide complementary to the siRNA targeted to the wild-type PBS complementary to
tRNALys,3. Following washing, the blot was autoradiographed. The order of samples was as follows: lane 1, RNA from cells transfected with NL4-His; lane 2,
RNA from cells transfected with NL4-His-RNAi(Lys,3); and lane 3, RNA from cells transfected with NL4-His-RNAi(Glu). The location of the siRNA is
denoted by the arrow. (E) Growth of viruses following infection of SupT1 cells. Infections were initiated as described in Materials and methods. The p24
antigen was measured in the supernatant at weekly time points for up to 5 weeks following the initiation of infection. The infection with wild-type virus
proceeded at a rapid pace resulting in high levels of p24 antigen in the supernatant by 1–2 weeks post infection (not shown). Depicted is the p24 antigen
production from viruses derived from pNL4-His (solid circles) compared with viruses derived from transfection of NL4-His-RNAi(Lys,3) (open squares). The
rapid rise in increase of p24 antigen from weeks 3 to 4 for the virus derived from pNL4-His correlated with the appearance of virus with a primer-binding site
complementary to tRNALys,3 (see Table 1). A rapid rise in p24 concentration was found for viruses derived from NL4-His-RNAi(Lys,3) at weeks 6 through 8
following infection (data not shown), coinciding with the reversion of the PBS to be complementary to tRNALys,3 and deletion of the gene encoding siRNA.
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appearance of large multinucleated giant cell syncytia in
the cultures. In contrast, the replication of the NL4-His-
RNAi(Lys,3) virus was delayed compared to that of NL4-
His. In this experiment, there was a 2–3-week delay in the
production of p24 antigen in the culture supernatant (Fig.
4E); a repeat of this experiment showed a similar delay
(data not shown). Eventually, the virus cultures with NL4-
His-RNAi(Lys,3) exhibited a rapid increase in p24 antigen
peaking at a level approximately the same as that for NL4-His. Virus derived from NL4-His-RNAi(Glu) were also
slightly delayed compared to NL4-His, exhibiting a rapid
rise in p24 by week 4 (data not shown).
Analysis of the PBS from NL4-His and
NL4-His-RNAi(Lys,3)
The PBS sequences from the integrated proviruses NL4-
His and NL4-His-RNAi(Lys,3) were analyzed at various
times during the infection. Consistent with our previous
Table 1
Analysis of PBS from NL4-His and NL4-His-RNAi at different times of
infection
Timea (weeks) PBS (wt/total)b
5 NL4-His 7/8
6 NL4-His-RNAi (Lys,3) 0/5
NL4-His-RNAi (Glu) 4/5
8 NL4-His 13/16
NL4-His-RNAi (Lys,3) 3/6
NL4-His-RNAi(Glu) 5/5
a Time refers to the length of time viruses in culture.
b PBS (primer binding site) was analyzed by PCR of high molecular weight
DNA followed by TA cloning of the product. The PBS and surrounding 5V
region was sequenced. The values represent numbers of WT (wild type)
PBS complementary to tRNALys,3 divided by the total number of individual
plasmids analyzed.
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supernatant increased from cells infected with NL4-His, the
PBS recovered from integrated proviruses had reverted
back to be complementary to tRNALys,3 (Table 1).
Essentially, at later times post infection, all recovered
PBS were complementary to tRNALys,3, indicating that the
wild-type virus was now predominant in the culture. In
contrast, NL4-His-RNAi(Lys,3) virus maintained a PBS
complementary to tRNAHis for a longer period of time
during the culture. The maintenance of the PBS comple-
mentary to tRNAHis correlated with the low production of
p24 antigen from virus-infected cells. The appearance of
the PBS complementary to tRNALys,3 was coincident with
the increase in p24 antigen levels. The NL4-His-
RNAi (Glu) reverted to use tRNALys,3 slightly slower than
NL4-His; by 6 weeks, 80% of the recovered clones had a
PBS complementary to tRNALys,3 while NL4-His-siR-
NA(Lys,3) still contained PBS complementary to tRNAHis.
Most probably, siRNA targeted to the wild-type PBS in
NL4-His-RNAi(Lys,3) inhibited the replication of revertant
virus with a PBS complementary to tRNALys,3. Reversion
to the wild type occurred fast in the cultures of NL4-His orTable 2
siRNA sequence following long term in vitro culture
Weeksa
NL4-His-RNAi(Lys,3): TGGCGCCCGAACAGGGACGATGC
5 TGGCGCCCGAACAGGGACGATGC
6 TGGCGCCCGAACAGGGACGATGC
TG. . . . . . . . . . . . . . . . . .GGGTATCGc.
8 #d. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
#. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
TGGCG. . . . . . . . . . . . . . . . . . . . . . .#. . .
NL4-His-RNAi(Glu): TGGTTCCCTGACCGGGAAGATGC
8 TGGTTCCCTGACCGGGAAGATGC
a Weeks of culture for designated sample.
b Frequency of sequence/total number sequenced.
c This clone contained the insertion of the sequence in bold.
d Sequence deleted from starting NL4-His-RNAi(Lys,3). Thus, the sequence rec
sequence for RNAi (Lys,3).NL4-His-RNAi(Glu), as evident from the analysis of the
PBS and rapid rise in p24 in these cultures.
Analysis of siRNA gene following replication
We next analyzed the gene encoding siRNA present in
integrated proviral genomes from NL4-His-RNAi(Lys,3)
virus at various times during the culture. Initially, all of the
PCR clones that we recovered contained intact U6 promoter
and siRNA gene sequences. Consistent with the results
obtained from the analysis of the PBS, at all times when the
sequence of the PBS was complementary to tRNAHis, we
obtained full-length siRNA sequences (Table 2, week 5).
However, at later times during the infection, prior to the
emergence of high-level p24 antigen in the culture super-
natants, PCR clones in which the siRNA gene was deleted
or truncated were recovered, resulting in an inactive siRNA
(Table 2, week 8). Thus, the results of these studies suggest
that the initial event in the evolution of this virus in culture
was probably the deletion of the gene encoding the siRNA
molecule. Once the siRNA was deleted, the selection of
viruses in which the PBS had reverted back to utilize
tRNALys,3 occurred resulting in high-level virus replication.
To substantiate this point, we analyzed the replication and
stability of NL4-His-RNAi(Glu). Analysis of the gene
encoding the siRNA revealed no changes from the starting
gene (Table 2). Thus, there appears to be no selection
against viruses that have an siRNA targeted to a PBS
complementary to tRNAGlu as there was against viruses
with an siRNA targeted to the wild-type PBS complemen-
tary to tRNALys,3.Discussion
In this report, we have shown that an siRNA duplex
targeted to the PBS region specifically decreased the amountFrequencyb
ATGGTCCCTGTTCGGGCGCCATTTTTT
ATGGTCCCTGTTCGGGCGCCATTTTTT 4/4
ATGGTCCCTGTTCGGGCGCCATTTTT 3/4
. . . . . . . . .TCCCTGTTCGGGCGCCATTTTT 1/4
. . . . . . . . . . . .CTGTTCGGGCGCCATTTTT 1/3
.ATGGTCCCTGTTCGGGCGCCATTTTT 1/3
. . . . . . . . . . . . . . . . . . . . . . . GGCGCCATTTTT 1/3
ATGTTCCCGGTCAGGGAACCATTTTT
ATGTTCCCGGTCAGGGAACCATTTTT 3/3
overed only contained CTGTTCGGGCGCCATTTTT in place of the full
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siRNA targeted to viral gag mRNA, while a control siRNA
targeted to gfp mRNA had no effect. No effect was seen on
total levels of tRNALys,3 with any siRNAs tested and total
protein synthesis was also not affected in cells transfected
with any of these siRNA molecules. An siRNA hairpin
targeted to the PBS expressed from an AAV vector similarly
inhibited HIV-1 replication in SupT1 cells. Finally, a HIV-1
proviral genome in which the PBS was altered to be
complementary to tRNAHis, which included a gene encod-
ing an siRNA that is targeted to the wild-type PBS was
studied to determine if this siRNA could provide stability to
the PBS of this provirus. Viral genomes that encoded the
siRNA targeted to the wild-type PBS maintained the PBS
complementary to tRNAHis for longer periods of in vitro
culture. Eventually, the PBS of these genomes reverted to be
complementary to tRNALys,3. Prior to the reversion, we
detected genomes in which the siRNA was truncated,
making it ineffective against inhibition of the wild-type
genome. Collectively, the results of these studies demon-
strate that siRNA can access the PBS resulting in inhibition
of viral replication.
The 18-nucleotide PBS of HIV-1 complementary to the
3V terminal 18 nucleotides of tRNALys,3 is absolutely
conserved among all HIV-1 (Colicelli and Goff, 1986; Lund
et al., 1993; Marquet et al., 1995; Ratner et al., 1985). A
complete deletion of the PBS results in a loss of virus
infectivity. However, if only the first six nucleotides of the
PBS remain, the virus was still infectious and upon
replication regenerated the complete 18-nucleotide PBS
(Rhim et al., 1991). This regeneration occurs during the
synthesis of plus strand DNA in which the reverse
transcriptase recopies the attached (tRNALys,3) primer to
generate a complete 18-nucleotide PBS (Gilboa et al., 1979;
Ratner et al., 1985; Taylor, 1977; Varmus, 1982). Thus,
HIV-1 is genetically programmed to maintain a complete
18-nucleotide PBS. Based on previous studies from this
laboratory and others, the HIV-1 PBS has an exceptionally
strong preference for the use of tRNALys,3. The PBS then
would appear to represent and ideal target for siRNA
designed to inhibit HIV-1 replication. Previous studies have
reported on the use of siRNA to inhibit HIV-1 replication
(Boden et al., 2003a; Capodici et al., 2002; Coburn and
Cullen, 2002; Jacque et al., 2002; Lee et al., 2002; Novina et
al., 2002; Park et al., 2003; Surabhi and Gaynor, 2002).
With respect to an siRNA targeted to tat, it was shown that
after 25 days of exposure to this shRNA the tat gene
contained a single point mutation that allowed the virus to
escape the effects of RNAi. Recently, Das et al. (2004)
demonstrated that siRNAs targeted to nef inhibited virus
replication upon extended in vitro culture, mutant viruses
were found that had deleted, or re-arranged the siRNA target
sequence in nef, allowing high-level virus replication.
Although not directly tested, presumably this would also
be the case with siRNAs targeted to other genes in the HIV-
1 genome.In our study, we have shown using three different
approaches that siRNA targeted to the PBS results in
inhibition of virus replication. Our results are in contrast
to a recent study by Das et al. (2004) that found siRNA
hairpins targeted to the PBS did not result in inhibition
of virus replication. While we cannot immediately
reconcile these results, there were several differences in
the studies that might have an impact on the subsequent
capacity of siRNA to inhibit replication. First, we
demonstrated that direct transfection of siRNA resulted
in the inhibition of virus replication in a manner similar
to that shown for siRNA targeted to gag described in a
previous study (Capodici et al., 2002). Our results are
consistent with a previous report that modified antisense
oligonucleotides targeted to the PBS inhibited virus
replication (Freund et al., 2001). Second, the design of
our hairpin siRNA was slightly different from that
described by Das et al. (2004). Our siRNA hairpins
contained the exact 18-nucleotide PBS (in contrast to 21
nucleotide) with a larger predicted loop sequence than
that described by Das et al. (2004). Additional differences
between the two studies include choice of RNA pol III
promoters (U6 compared to H1), which could influence
the potency of inhibition (Boden et al., 2003b). Whether
or not the nucleotide differences or the AAV expression
system (as compared to a retroviral expression system in
Das et al., 2004) could result in the differences seen will
require further experimentation.
To further substantiate the inhibition by siRNA, we
made use of a unique HIV-1 provirus with a PBS
complementary to tRNAHis (Wakefield et al., 1996).
Alteration of the PBS alone to be complementary to
tRNAHis resulted in an unstable virus that reverted back
to utilize tRNALys,3 after a short term of in vitro culture. In
order to maintain the virus that uses tRNAHis, additional
mutations encompassing six nucleotides in the A-loop
region and three nucleotides in U5 were required. These
mutations were all contained within the RNA stem loop
structure that has been postulated for the U5-PBS region.
Previous studies from this laboratory and others have
suggested that this RNA stem loop is important for the
selection of the tRNA primer used by HIV-1 to initiate
reverse transcription (Isel et al., 1993, 1995, 1996; Kang et
al., 1999; Zhang et al., 1998). However, after extended
culture, rather than finding HIV-1 that evolved to more
effectively use tRNAHis, we found genomes with a deleted
siRNA gene. The selection for viruses with a deleted
siRNA strongly implies that the siRNA targeted to the
wild-type PBS inhibited replication of virus with a wild-
type PBS. We do not think the siRNA structure positioned
in the viral genome at this location is inherently unstable,
since the siRNA targeted to the PBS complementary to
tRNAGlu was recovered intact following replication. Rather,
during replication (reverse transcription), the siRNA genes
are bypassed possibly due to the formation of the RNA
hairpin within the genomic RNA, leading to deletion of the
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PBS would allow selection for the wild-type PBS
(complementary to tRNALys,3). This virus would then
outgrow the mutant with a PBS complementary to
tRNAHis. In contrast, deletion of the siRNA targeted to
the PBS complementary to tRNAGlu would not give a
selective advantage and the virus would revert to use
tRNALys,3 regardless of the state of the siRNA gene. Thus,
we did not recover NL4-His-RNAi(Glu) viruses with
deletions in the siRNA. Collectively, the results of these
studies support that siRNA targeted to the PBS inhibit
replication and underscores the evolution of HIV-1 to
preferentially select tRNALys,3 for replication.
Finally, the capacity of HIV-1 replication to be inhibited
by siRNA provides insights into the mechanism of primer
tRNA selection by HIV-1. In a recent study, the effects of
tight RNA structure, sequence, and position of target RNA
on the activity of siRNAs were evaluated (Yoshinari et al.,
2004). This study found that the activity of the siRNA was
most affected by a tight stem-loop RNA structure; that is,
the efficacy of the siRNA inhibition was reduced when the
target site was located within a tight RNA structure.
Extending this concept to the U5-PBS, we would suggest
that the U5-PBS is probably not embedded within a
constructed RNA structure. How does this impact on the
primer selection process? Previous studies from this
laboratory and others have shown that alteration of the
PBS to be complementary to alternative tRNAs (i.e., not
tRNALys,3) results in the transient use of these tRNAs for
initiation of reverse transcription (Das et al., 1995; Li et
al., 1994; Wakefield et al., 1995). These results suggest
that during primer selection, the virus probably has access
to a pool of different cellular tRNAs. Indeed, recent studies
from this laboratory have shown that the selection of the
tRNA primer used for HIV-1 replication is most probably
coupled with translation (Kelly et al., 2003). The fact that
the siRNA targeted to the U5-PBS can access this region
within the cell supports the concept that complementarity
of the PBS and target tRNA is important in the selection
process. Previous studies from this laboratory have
reported that modifications within the U5-PBS allowed,
in some instances, HIV-1 to select alternative tRNAs for
replication (Kang and Morrow, 1999; Kang et al., 1997,
1999; Wakefield et al., 1996; Zhang et al., 1998).
Complementarity between the U5-PBS target tRNA
facilitates the initial interaction and possible selection as
the primer for reverse transcription. Why tRNALys,3 is
preferred as a primer for initiation of reverse transcription
is not clear. Undoubtedly, it involves the intracellular
availability of tRNALys,3 coupled with potentially unique
features of the tRNA that facilitate the selection process.
The future use of the siRNAs described in this study
should provide us with additional reagents to probe the
RNA structures associated with the U5-PBS that are
involved in selection of the tRNA primer required for
HIV-1 replication.Materials and methods
Tissue culture
The SupT1 cells were maintained in RPMI (Mediatech)
supplemented with 10% FBS and antibiotics in 37 8C
incubator supplied with 5% CO2; the COS-1 cells were
maintained in DMEM (Invitrogen) supplemented with 10%
FBS and antibiotics.
siRNA preparation
Oligonucleotides were synthesized (Invitrogen, Carlsbad,
CA) as follows. GAG-AS: 5V-AAGGGCAAGCAGG-
GAGCTAGAACTATAGTGAGTCGTATTACC-3V.
GAG-S: 5V-AGGTTCTAGCTCCCTGCTTGCCCTATAGT-
GAGTCGTATTACC-3V. PBS-AS: 5V-AA AGTGGCGCCC-
GAACAGGGACCTATAGTGAGTCGTATTACC-3V.
PBS-S: 5V-A AGGTCCCTGT TCGGGCGCCACCTA-
TAGTGAGTCGTATTACC-3V. GFP-AS: 5V-GGGGTG-
CGCTCCTGGACGT AGCCTATAGTGAGTCGTAT-
TACC-3V. GFP-S: 5V-AAGGCTACGTCCAGGAGCGCA-
CCTATAG TGAGTCGTATTACC-3V. T7: 5V-GGTATT-
ACGACTCACTATA GG-3V. The T7 oligonucleotide
was annealed to each of the other oligonucleotides in
equimolar amounts in siRNA annealing buffer (10 mM
Tris–HCl, pH 8, 100 mM NaCl) by heating at 95 8C
for 2 min followed by cooling to room temperature
over 1 h. The annealed oligonucleotides were tran-
scribed in vitro using the T7-MEGAshortscript High
Yield Transcription Kit (Ambion, Austin, TX) overnight
at 37 8C. DNase I was added to the overnight
transcription samples which were incubated for 15
min at 37 8C. The RNA was ethanol precipitated
and resuspended in siRNA annealing buffer. Single-
stranded RNAs were annealed to their complimentary
RNA (antisense and sense strands) by heating to
95 8C for 2 min and cooling to room temperature
over 1 h. Double-stranded RNAs were purified on a
12% nondenaturing polyacrylamide gel run at 4 8C and
eluted overnight. Purified products were ethanol pre-
cipitated and resuspended in 20 Al siRNA annealing
buffer.
Transfection of siRNAs
SupT1 cells (5  105) were transfected with 100
pmol siRNA duplex using Lipofectamine 2000 (Invitro-
gen) in a final volume of 700 Al Opti-MEM. Trans-
fections were incubated for 4 h at 37 8C. Cells were
pelleted and washed with RPMI 1640 with 15% FBS.
Cells were infected with 50 pg NL4-3 virus (Adachi et
al., 1986) in 200 Al RPMI 1640 with 15% FBS for 2 h
at 37 8C and mixed every 30 min. One-milliliter RPMI
1640 with 15% FBS was added to the infection and
200 Al of the supernatant was taken for a Day 0 sample.
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with 500 Al fresh RPMI 1640 with 15% FBS. p24 levels
were determined using p24 ELISA kits (Coulter, Miami,
FL).
Construction of siRNA cDNA hairpins
The siRNA-Lys,3 were designed to target the PBS of
HIV-1. A second RNA, siRNA-Glu, was designed to target
the PBS complementary to tRNAGlu. The siRNA were
designed to form a hairpin structure with an 18-nt-long
dsRNA, 8-nt loop, and symmetrical 2- to 3-nt 3Voverhangs
(Figs. 3A,B). Two oligonucleotides corresponding to the
sense and antisense strands of the siRNAwere used to create
the gene encoding the siRNA. For the siRNA to be
complementary to the wild-type virus PBS complementary
to tRNALys,3, the following oligonucleotides were used:
siRNA-Lys,3 oligo 1: 5V ACACCCTCGAGGTCCTGG-
CGCCCGAACA GGGACGATGCATG-GTCC 3V and
siRNA-Lys,3 oligo 2: 5V ACACCAAGCTTAATCTGG-
CGCCC GAACAGGGACCATGCATCGT 3V. For the gene
encoding siRNA to the PBS complementary to tRNAGlu, the
following oligonucleotides were used: siRNA-Glu oligo 3:
5V ACACCCTCGAGGTCCT GGTTCCCTGACCGGG-
AAGATGCATG-TTCCC 3V and siRNA-Glu oligo 4: 5V
CACCAAGCTTAA TCAAAAAA-TGGTTCCCTGA-
CCGGGAACATGCATCTT 3V. PCR was used with the
appropriate oligonucleotides (oligo 1 and 2, or 3 and 4 as
primer and template) to generate the full-length siRNA. The
oligonucleotides were designed to include an XhoI at 5Vand
HindIII at 3Vend to facilitate cloning. The cDNAs encoding
the siRNAs were cloned into pLS9 (Lobo and Hernandez,
1989), a plasmid that contains the U6 RNA polymerase III
promoter immediately upstream from XhoI–HindIII restric-
tion sites.
Construction of HIV encoding siRNA
To subclone the U6-siRNA gene into the HIV-1
proviral genome (NL4-3) (Adachi et al., 1986); a DNA
fragment encompassing nef in a BamHI–XbaI restriction
fragment was subcloned into pLitmus28i, which contains
a single BlpI site. A new restriction site (MfeI, under-
lined) was created using PCR mutagenesis with the
following primers: pimer 1: 5V-ACAGCAGCTAC-
CAATTGTGCTTGTGCCTGGCT-3V; primer 2: 5V-AGC-
CAGGCAC AAGCACAATTGGTAGCTGCTGT-3V;
primer 3: 5V-GGATATCTGGATCCTTGG-3V; primer 4: 5V-
CTCACCTAGGTATCTAGA-3V.
To subclone the U6-siRNA genes into the transfer
plasmid, oligonucleotides were designed to amplify the
gene and create BlpI–MfeI restriction sites (underlined):
5V: 5V-ACAGGACGCTGAGCCC TATTTCCCAT-
GATTCCTTCATATT-3V; 3V: 5V-ACAGGCAATTGACAC-
CAAGCTTAATCAAAA AATGGCG-3V. The U6-siRNA
was then subcloned into the pLitmus transfer plasmidusing BlpI and MfeI. The BamHI–XbaI fragment was
then recloned into the full-length proviral clone, pNL4-3.
The complete U6-siRNA gene was sequenced in pNL4-3
prior to use.
The proviral DNAs (10 Ag) were transfected into COS-
1 cells using Lipofectamine 2000 (Invitrogen), and the
supernatant was collected 48 h after transfection. The virus
concentration was determined by a p24 ELISA (Abbott
Laboratories); the infectivity was determined using a
bioassay as previously described (Derdeyn et al., 2000).
A total of 300 pg (as determined by p24) virus was used to
infect 5  105 SupT1 cells under standard conditions
(Kang et al., 1999).
Construction of adeno-associated virus (AAV) encoding
siRNA
To express the siRNAs using AAV, we used the AAV
Helper-Free System from Stratagene (La Jolla, CA). The
cDNAs for the siRNAs were amplified from the proviral
constructs NL4-His-siRNA (to PBS complementary to
tRNALys,3 or tRNAGlu) using a 5V oligonucleotide
upstream of the U6 promoter that created a BglII
restriction site (underlined; TTCC AGATCT CCTAT
TTCCC ATGAT TCCTTC) and an oligonucleotide down-
stream of the termination sequence encompassing a
HindIII restriction site (within the HIV-1 genome;
GTCTC GAGAT GCTGC TCCCA). The resultant PCR
product was digested with BglII–HindIII and subcloned
into pCMV-MCS between the BglII–HindIII sites in the
multiple cloning region. The position of the inserted U6-
siRNA was opposite to the CMV promoter. The plasmids
encoding siRNA targeted PBS complementary to
tRNALys,3 (AAV-Lys) or tRNAGlu (AAV-Glu) were con-
firmed by sequencing prior to transfection.
The recombinant AAV was produced following the
manufacturer’s instructions using CaPO4 transfection into
HEK293 cells. The viral titer was estimated by comparison
with a control vector, pAAV-Lac Z, produced in an
identical way as the AAV encoding siRNA. The virus
was prepared from transfected cells according to the
manufacturer’s instructions. The released AAV was con-
centrated by ultracentrifugation in an SW41 rotor (40,000
rpm) for 18 h. The pelleted material was re-suspended in
1/10 volume of DMEM minus serum. The viral titer was
estimated to be approximately 5  106 infectious units/ml
for each AAV.
SupT1 cells (2  105) were infected with AAV at a
MOI of 5 in a reduced volume for 2 h. After that time,
the cells were diluted to 1  105 cells/ml for 24 h at 37
8C in complete medium. To infect with HIV-1, cells were
first pelleted by centrifugation (800  g for 10 min), and
infected with 50 pg NL4-3 HIV-1 for an approximate
MOI of 0.01 The infection was monitored by visual
inspection of syncytia formation and analysis of p24
antigen using an ELISA.
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integrated proviruses
High molecular weight DNA (HMW) was collected
using Wizard Genomic DNA Purification Kit (Promega).
The region encompassing the PBS was amplified by PCR
using the following primers: (forward) 5V-TAGACCA-
GATCTGAGCCTGGGAGCTC-3V and (reverse) 5V-
CTCCTTCTAGCCTCC GCTAGTC-3V. The following
primers were used to amplify the U6-RNAi gene:
(forward) 5V-ACAGGACGCTGAGCCCTATTTCCCAT-
GATTCCTTCATATT-3V and (reverse) 5V-GTCTCGAGA
TGCTGCTCCCA-3V. Following PCR, the products were
cloned into TA vectors as previously described (Moore et
al., 2004); DNA sequencing of individual clones was done
using automated DNA sequencing.
Northern blot
Northern blot was carried out using NorthernMax-Gly
kit (Ambion) using previously described conditions for
isolation of total RNA. The probe for siRNALys,3, 5V-
TGGCGCCC GAACAGGGACCATGCATCGTCCC-
TGTTCGGGCGCCA-3V, was phosphorylated using the
ready to-go kit (Amersham) with [g-32P-ATP]. The specific
activity of the probe was approximately 1.17  107 cpm/
pmol. Hybridization was carried out under standard
conditions. The radioactivity was visualized by auto-
radiography as previously described (Kelly et al., 2003).Acknowledgments
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